Simon L. Croft
YOU?
Author Swipe
View article: Comparative in vitro susceptibility of clinical Leishmania isolates to miltefosine and oleylphosphocholine
Comparative in vitro susceptibility of clinical Leishmania isolates to miltefosine and oleylphosphocholine Open
Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania . It poses a significant global health burden, particularly because treatment options are limited. More effective and safer …
View article: In vitro models in drug discovery and development for leishmaniasis: A perspective
In vitro models in drug discovery and development for leishmaniasis: A perspective Open
The intracellular Leishmania amastigote model (ILAM) has been instrumental in advancing drug discovery for leishmaniasis treatment over the past 40 years. This review explores the evolution and current applications of ILAMs in screening an…
View article: Comparative assessment of macrophage responses and antileishmanial efficacy in dynamic vs. Static culture systems utilizing chitosan-based formulations
Comparative assessment of macrophage responses and antileishmanial efficacy in dynamic vs. Static culture systems utilizing chitosan-based formulations Open
The discovery of novel anti-leishmanial compounds is essential due to the limitations of current treatments and the lack of new drugs in development. In this study, we employed the Quasi Vivo 900 medium perfusion system (QV900, Kirkstall L…
View article: Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis Open
Objectives Cutaneous leishmaniasis (CL) is a neglected tropical disease causing a range of skin lesions for which safe and efficacious drugs are lacking. Oleylphosphocholine (OLPC) is structurally similar to miltefosine and has previously …
View article: Dermal microdialysis: a method to determine drug levels in the skin of patients with Post Kala-azar Dermal Leishmaniasis (PKDL)
Dermal microdialysis: a method to determine drug levels in the skin of patients with Post Kala-azar Dermal Leishmaniasis (PKDL) Open
Objectives Post-kala-azar-dermal leishmaniasis (PKDL) is an infectious skin disease that occurs after apparent cure from visceral leishmaniasis (VL) and causes stigmatizing lesions on the face and other exposed body parts. While the first-…
View article: Challenges of using modelling evidence in the visceral leishmaniasis elimination programme in India
Challenges of using modelling evidence in the visceral leishmaniasis elimination programme in India Open
As India comes closer to the elimination of visceral leishmaniasis (VL) as a public health problem, surveillance efforts and elimination targets must be continuously revised and strengthened. Mathematical modelling is a compelling research…
View article: Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug
Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug Open
Background Human African trypanosomiasis (HAT or sleeping sickness) is caused by the parasite Trypanosoma brucei sspp . The disease has two stages, a haemolymphatic stage after the bite of an infected tsetse fly, followed by a central nerv…
View article: Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis Open
In cutaneous leishmaniasis (CL), parasites reside in the dermis, creating an opportunity for local drug administration potentially reducing adverse effects and improving treatment adherence compared to current therapies. Polymeric film-for…
View article: Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis Open
Background There is a continued need to develop effective and safe treatments for visceral leishmaniasis (VL). Preclinical studies on pharmacokinetics and pharmacodynamics of anti-infective agents, such as anti-bacterials and anti-fungals,…
View article: Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, India
Costs and outcomes of active and passive case detection for visceral leishmaniasis (Kala-Azar) to inform elimination strategies in Bihar, India Open
Background Effective case identification strategies are fundamental to capturing the remaining visceral leishmaniasis (VL) cases in India. To inform government strategies to reach and sustain elimination benchmarks, this study presents cos…
View article: Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities
Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities Open
Important pharmacokinetic and -dynamic parameters for the drug discovery and development of new treatments for cutaneous leishmaniasis.
View article: Marine alkaloids as bioactive agents against protozoal neglected tropical diseases and malaria
Marine alkaloids as bioactive agents against protozoal neglected tropical diseases and malaria Open
This Review discusses the isolation and bioactivity of marine alkaloids against protozoan parasite diseases, and chemical syntheses that enable the further development of these scaffolds as drug leads.
View article: Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis
Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis Open
The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via differen…
View article: Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis
Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis Open
Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported antimicrobial and anti-leishmanial activities. We investigated the application …
View article: Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs
Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs Open
The discovery of novel anti-leishmanial compounds remains essential as current treatments have known limitations and there are insufficient novel compounds in development. We have investigated three complex and physiologically relevant in …
View article: Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana <i>In Vitro</i>
Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana <i>In Vitro</i> Open
There is an urgent need for safe, efficacious, affordable, and field-adapted drugs for the treatment of cutaneous leishmaniasis, which newly affects around 1.5 million people worldwide annually. Chitosan, a biodegradable cationic polysacch…
View article: Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis Open
Background: Liposomal amphotericin B (AmBisome®) as a treatment modality for visceral leishmaniasis (VL) has had significant impact on patient care in some but not all regions where VL is endemic. As the mode of action of AmBisome® in vivo…
View article: An Efficient and Novel Technology for the Extraction of Parasite Genomic DNA from Whole Blood or Culture
An Efficient and Novel Technology for the Extraction of Parasite Genomic DNA from Whole Blood or Culture Open
Supplemental file 1 for: An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture Supplementary Figure 1: Plasmodium falciparumDNA from spiked whole blood determined by PfBetatubulin PCR. A a…
View article: Innovations for the elimination and control of visceral leishmaniasis
Innovations for the elimination and control of visceral leishmaniasis Open
Visceral leishmaniasis (VL), a disease associated with poverty, is endemic in the Indian subcontinent and Africa (where it is caused by the protozoan parasite Leishmania donovani, and in Latin America and the Mediterranean region (where it…
View article: Development of an in vitro media perfusion model of Leishmania major macrophage infection
Development of an in vitro media perfusion model of Leishmania major macrophage infection Open
Perfusion of culture medium in an in vitro L. major macrophage infection model (simulating in vivo lymphatic flow) reduced the infection rate of macrophages, the replication of the intracellular parasite, macrophage phagocytosis and macrop…
View article: Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis Open
The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that also shows potent in vitro and in vivo activity against cutaneous leishmaniasis (CL). To support further development of this compound into a pat…
View article: Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis Open
Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limit…
View article: Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug
Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug Open
Human African trypanosomiasis (HAT or sleeping sickness) is caused by the parasite Trypanosoma brucei sspp. The disease has two stages, a haemolymphatic stage after the bite of an infected tsetse fly, followed by a central nervous system s…
View article: Leishmaniasis – Authors' reply
Leishmaniasis – Authors' reply Open
View article: Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis Open
View article: Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis
Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis Open
Background: Human visceral leishmaniasis, caused by infection with Leishmania donovani or L. infantum, is a potentially fatal disease affecting 50,000-90,000 people yearly in 75 disease endemic countries, with more than 20,000 deaths repor…
View article: Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis
Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis Open
Background: Human visceral leishmaniasis, caused by infection withLeishmania donovaniorL. infantum,is a potentially fatal disease affecting 50,000-90,000 people yearly in 75 disease endemic countries, with more than 20,000 deaths reported.…
View article: Leishmaniasis
Leishmaniasis Open
View article: Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B Open
Disfiguring skin lesions caused by several species of the Leishmania parasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate …
View article: Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis Open